Does taking Nexium (esomeprazole) increase the risk of Clostridioides difficile infection, and should it be discontinued or switched to an H2‑receptor antagonist?

Nexium and C. difficile Infection Risk

While there is a clear epidemiologic association between Nexium (esomeprazole) and other PPIs with increased C. difficile infection risk, current guidelines state there is insufficient evidence to recommend discontinuing PPIs solely as a CDI prevention measure—however, unnecessary PPIs should always be stopped. 1

The Evidence on PPI-CDI Association

The FDA drug label for Nexium explicitly warns that "published observational studies suggest that PPI therapy like NEXIUM may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients" and recommends using "the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated." 2

Multiple research studies demonstrate this association:

• Dose-dependent risk: Higher PPI doses correlate with greater CDI risk (adjusted hazard ratio 2.0 for high dose vs 1.3 for medium dose), with risk increasing even with exposure periods as short as 6 days 3
• Nosocomial settings: Risk increases progressively from no acid suppression (0.3%) to H2RA therapy (0.6%) to daily PPI (0.9%) to more frequent PPI dosing (1.4%), with adjusted odds ratios reaching 2.36 for frequent PPI use 4
• Community-acquired CDI: PPIs increase risk 2.9-fold compared to 2.0-fold for H2RAs 5
• Recurrent CDI: PPI use during hospitalization increases recurrence risk by 84% (OR 1.84) 6
• Combined effects: Recent PPI plus antibiotic use shows synergistic risk elevation (OR 17.51) greater than either alone 7

The mechanism appears to be pH-mediated rather than direct microbiome disruption—elevated gastric pH allows C. difficile spores to survive gastric passage 8

Clinical Decision Algorithm

For Patients WITHOUT Active CDI:

Do NOT routinely discontinue PPIs solely for CDI prevention, as the 2018 IDSA/SHEA guidelines explicitly state there is insufficient evidence for this approach 1. However:

1. Immediately assess PPI indication: Review whether the PPI is medically necessary
2. Discontinue if no clear indication exists (stewardship principle strongly supported) 9
3. If PPI is necessary: Use the lowest effective dose for the shortest duration 2
4. Consider H2RA alternative in high-risk patients (elderly, multiple antibiotics, prior CDI, ICU patients) where acid suppression is needed but indication is marginal 10

For Patients WITH Active CDI:

The guidelines are more nuanced here:

1. Assess PPI necessity: Evaluate whether the PPI indication is compelling
2. If PPI is unnecessary: Discontinue it 9
3. If PPI is medically necessary: The 2018 IDSA/SHEA guidelines make no recommendation to discontinue PPIs as a CDI treatment measure, despite the association 1
4. For recurrent CDI: Consider discontinuing PPIs as continued use is associated with increased recurrence risk 1

Key Caveats and Pitfalls

The critical distinction: The epidemiologic association is robust and dose-dependent, but randomized controlled trials demonstrating that PPI discontinuation reduces CDI incidence are lacking. This explains why guidelines acknowledge the association but stop short of mandating discontinuation 1, 9.

Common pitfall: Reflexively continuing PPIs in hospitalized patients without reassessing indication. Studies show many hospitalized patients receive PPIs without appropriate indication—these should be stopped regardless of CDI concerns 9.

High-risk populations warrant extra scrutiny: ICU patients on PPIs have 3.3-fold increased odds of CDI compared to H2RAs 10. In these settings, if acid suppression is needed but the indication is not absolute, H2RAs represent a safer alternative.

Recurrent CDI is different: While guidelines don't recommend PPI discontinuation for initial CDI prevention, the association with recurrence is concerning enough that unnecessary PPIs should be aggressively deprescribed in patients with prior CDI 1, 6.